GlassScriptPhysician profile
Frederick Carl Martinez
NPI 1497849483
$3,488.35
in general payments reported to CMS, 2019-2025
36 companies · $576 in 2025
The $576 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $48.33 · 2021: $15.54 · 2022: $710 · 2023: $501 · 2024: $846 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $609.29 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Ethicon US, LLC | $341.61 | 2019-2024 | Monocryl, Echelon; Endopath, Dermabond |
| Pfizer INC. | $260.86 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $208.41 | 2022-2025 | Prolaris |
| Boston Scientific Corporation | $178.00 | 2019-2024 | Lithovue |
| Endo Pharmaceuticals INC. | $147.35 | 2019-2023 | Xiaflex |
| Endo USA, INC. | $129.82 | 2024-2025 | Xiaflex, Aveed |
| Procept Biorobotics Corporation | $117.03 | 2019-2025 | Aquabeam System |
| Coloplast Corp | $108.42 | 2019-2025 | |
| Abbvie INC. | $97.69 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.95 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $92.56 | 2023 | Gemtesa, Orgovyx |
| Ambu INC. | $90.85 | 2023-2024 | |
| Axonics, INC. | $90.40 | 2022-2024 | Axonics |
| Janssen Biotech, INC. | $82.85 | 2024-2025 | Erleada |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $75.32 | 2025 | Bard Urinary Drainage Bag |
| Stryker Corporation | $71.43 | 2024 | 1788 |
| Olympus America INC. | $64.31 | 2025 | Itind System |
| Urogen Pharma, INC. | $58.08 | 2025 | |
| Urovant Sciences INC | $53.87 | 2022 | |
| Myovant Sciences INC. | $51.19 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $51.09 | 2025 | |
| Conmed Corporation | $48.71 | 2022 | |
| Neotract INC. | $45.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $45.07 | 2022 | |
| Progenics Pharmaceuticals, INC. | $43.49 | 2022-2024 | |
| Travere Therapeutics, INC. | $36.47 | 2019 | |
| Teleflex LLC | $33.42 | 2024-2025 | Urolift, Barrigel |
| Rochester Medical Corporation | $25.49 | 2022 | |
| Bard Access Systems, INC. | $24.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.69 | 2025 | |
| Agiliti Surgical, INC. | $22.40 | 2023 | Cryocare Cs, Sonablate |
| Alexion Pharmaceuticals, INC. | $20.33 | 2023 | Ultomiris |
| Merck Sharp & Dohme LLC | $17.61 | 2020 | |
| Accord Healthcare, INC. | $13.81 | 2023 | |
| Ferring Pharmaceuticals INC. | $13.07 | 2024 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.